Quantification of dimethyl-ifosfamide and its N-deschloropropylated metabolites in mouse plasma by liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 11-12, 2011, Pages 743-750

  Deroussent, Alain ^a,b   Rodriguez, Stéphanie ^a   Martelli, Sonia ^a   Seck, Atmane ^a   Dubus Daudigeos, Estelle ^a   Desmaële, Didier ^c   Vassal, Gilles ^a   Paci, Angelo ^a  

^a CNRS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SUD   (France)

Author keywords

Alkylating agents; Dimethyl ifosfamide; Liquid chromatography; Mouse plasma; Pharmacokinetics; Tandem mass spectrometry

Indexed keywords

BIOMOLECULES; CYTOTOXICITY; LIQUID CHROMATOGRAPHY; LIQUIDS; MAMMALS; MASS SPECTROMETRY; METABOLITES; METHANOL; PHARMACOKINETICS;

ALKYLATING AGENTS; IFOSFAMIDE; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; MOUSE PLASMA; MULTIPLE REACTION MONITORING; REVERSED PHASE CHROMATOGRAPHY; SENSITIVE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

7,9 DIMETHYLIFOSFAMIDE; CHLORINE DERIVATIVE; IFOSFAMIDE; N2 DECHLOROPROPYLDIMETHYLIFOSFAMIDE; N3 DECHLOROPROPYLDIMETHYLIFOSFAMIDE; PRODRUG; PROPANE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BLOOD LEVEL; FEMALE; LIQUID CHROMATOGRAPHY; METABOLITE; MOUSE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; RHABDOMYOSARCOMA; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

MUS;

EID: 79952898680     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.02.012     Document Type: Article

References (24)

1. Liang J., Huang M., Duan W., Yu X.Q., Zhou S. Curr. Pharm. Des. 2007, 13:963.
2. Siu L.L., Moore M.J. Support. Care Cancer 1998, 6:144.
3. Giraud B., Hebert G., Deroussent A., Veal G.J., Vassal G., Paci A. Expert Opin. Drug Metab. Toxicol. 2010, 6:919.
4. Boddy A.V., Yule S.M. Clin. Pharmacokinet. 2000, 38:291.
5. Kerbusch T., de Kraker J., Keizer H.J., van Putten J.W., Groen H.J., Jansen R.L., Schellens J.H., Beijnen J.H. Clin. Pharmacokinet. 2001, 40:41.
6. Granvil C.P., Madan A., Sharkawi M., Parkinson A., Wainer I.W. Drug Metab. Dispos. 1999, 27:533.
7. Roy P., Tretyakov O., Wright J., Waxman D.J. Drug Metab. Dispos. 1999, 27:1309.
8. Paci A., Guillaume D., Husson H.-P. J. Heterocycl. Chem. 2001, 38:1131.
9. Storme T., Deroussent A., Mercier L., Prost E., Re M., Munier F., Martens T., Bourget P., Vassal G., Royer J., Paci A. J. Pharmacol. Exp. Ther. 2009, 328:598.
10. Storme T., Mercier L., Deroussent A., Re M., Martens T., Royer J., Bourget P., Vassal G., Paci A. J. Chromatogr. B 2005, 820:251.
11. Oliveira R.V., Onorato J.M., Siluk D., Walko C.M., Lindley C., Wainer I.W. J. Pharm. Biomed. Anal. 2007, 45:295.
12. Gourmel B., Granvil C.P., Denis S.L., Wainer I.W., Bousquet B. J. Chromatogr. B 1999, 732:3.
13. Kaijser G.P., Beijnen J.H., Bult A., Kelzer H.J., Underberg W.J.M. J. Chromatogr. B 1997, 690:131.
14. Kerbusch T., Jeuken M.J., Derraz J., van Putten J.W., Huitema A.D., Beijnen J.H. Ther. Drug Monit. 2000, 22:613.
15. Granville C.P., Gehrcke B., Konig W.A., Wainer I.W. J. Chromatogr. 1993, 622:21.
16. Wang J.J., Chan K.K. J. Chromatogr. B 1995, 674:205.
17. Ekhart C., Gebretensae A., Rosing H., Rodenhuis S., Beijnen J.H., Huitema A.D. J. Chromatogr. B 2007, 854:345.
18. Chen X., Sun Y., Cao X., Jin F., Zhong D. Rapid Commun. Mass Spectrom. 2005, 19:1839.
19. Aleksa K., Nava-Ocampo A., Koren G. Chirality 2009, 21:674.
20. EMEA, International Conferences on Harmonization CPMP/ICH/281/95, 1997.
21. FDA, Homepage, Guidance for Industry: Bioanalytical Method Validation, 2001.
22. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Anal. Chem. 2003, 75:3019.
23. Kurowski V., Cerny T, Kiipfer A., Wagner T. J. Cancer Res. Clin. Oncol. 1991, 117:148.
24. Masurel D., Houghton P.J., Young C.L., Wainer I.W. Cancer Res. 1990, 50:252.